Association between low-dose aspirin use and kidney stone disease in middle-aged and older Americans: Data from the national health and nutrition examination survey 2011–2018

To evaluate the association between the low-dose aspirin use and kidney stone disease (KSD). This cross-sectional study enrolled participants from the National Health and Nutrition Examination Survey 2011–2018. Univariate and multivariate logistic regression analyses were conducted to investigate the association between low-dose aspirin use and KSD. A total of 12 989 middle-aged and elderly participants over 40 years old took part in the study, and 4122 participants reported using low-dose aspirin. After fully multivariate adjustment, no difference was found between low-dose aspirin use and KSD in the whole population (odds ratio [OR]=0.86, p =0.1). After grouped by hypertension, low-dose aspirin use was negatively associated with KSD in hypertensive individuals (OR=0.76, p =0.046), while no difference was found among people without hypertension (OR=1.00, p =1). In addition, among hypertensive individuals, with the increase of the dose of aspirin, the ORs tend to decrease gradually ( p for trend =0.020), although only the dose greater than 567 mg per week was negatively correlated with KSD (OR=0.49, p =0.009). The main limitation is the cross-sectional design of the study. Our findings suggest that low-dose aspirin use was negatively associated with KSD in the United States adults aged 40 years and above with hypertension. In addition, higher dose of aspirin use seems to be related to lower kidney stone prevalence. Further prospective researches are needed to confirm these findings.